112 related articles for article (PubMed ID: 8054488)
1. Anti-tumour effects of interleukin 1 beta: in vivo induction of immunity to B16 melanoma, a non-immunogenic tumour.
Neville ME; Pezzella KM
Cytokine; 1994 May; 6(3):310-7. PubMed ID: 8054488
[TBL] [Abstract][Full Text] [Related]
2. In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin 1 beta. II. Mechanism of inhibition: the role of polymorphonuclear leukocytes.
Neville ME; Pezzella KM; Schmidt K; Galbraith W; Ackerman N
Cytokine; 1990 Nov; 2(6):456-63. PubMed ID: 1966551
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of therapeutic effect of recombinant tumor necrosis factor against B16 mouse melanoma by combination with recombinant interleukin 2.
Urano K; Habu S; Nishimura T
Cytokine; 1993 May; 5(3):224-9. PubMed ID: 8218934
[TBL] [Abstract][Full Text] [Related]
4. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens.
Kim TS; Russell SJ; Collins MK; Cohen EP
Int J Cancer; 1992 May; 51(2):283-9. PubMed ID: 1533203
[TBL] [Abstract][Full Text] [Related]
5. Gene transfer of a hybrid interleukin-1 beta gene to B16 mouse melanoma recruits leucocyte subsets and reduces tumour growth in vivo.
Björkdahl O; Wingren AG; Hedhund G; Ohlsson L; Dohlsten M
Cancer Immunol Immunother; 1997 Jul; 44(5):273-81. PubMed ID: 9247562
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation.
García-Hernández ML; Hernández-Pando R; Gariglio P; Berumen J
Immunology; 2002 Feb; 105(2):231-43. PubMed ID: 11872099
[TBL] [Abstract][Full Text] [Related]
8. Effect of ultraviolet-inducible cytokines on melanoma growth in vivo: stimulation of melanoma growth by interleukin-1 and -6.
Mckenzie RC; Park ES; Brown WR; Shivji GS; Sauder DN
Photodermatol Photoimmunol Photomed; 1994 Apr; 10(2):74-9. PubMed ID: 8043388
[TBL] [Abstract][Full Text] [Related]
9. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
Kim TS; Xu WS; Sun T; Cohen EP
Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
[TBL] [Abstract][Full Text] [Related]
10. In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin 1 beta. I. Tumor inhibition parallels lymphocyte-activating factor activity of interleukin 1 beta proteins.
Pezzella KM; Neville ME; Huang JJ
Cytokine; 1990 Sep; 2(5):357-62. PubMed ID: 2103334
[TBL] [Abstract][Full Text] [Related]
11. Modulation of specific active immunization against murine melanoma using recombinant cytokines.
Stidham KR; Ricci WM; Vervaert C; Abdel-Wahab Z; Seigler HF; Darrow TL
Surg Oncol; 1996; 5(5-6):221-9. PubMed ID: 9129134
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity.
Seo N; Hayakawa S; Takigawa M; Tokura Y
Immunology; 2001 Aug; 103(4):449-57. PubMed ID: 11529935
[TBL] [Abstract][Full Text] [Related]
13. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
[TBL] [Abstract][Full Text] [Related]
14. Host immunity to mycoplasma antigens introduced into B16 melanoma cells: effect on tumor growth rate and metastasis.
Stackpole CW; Alterman AL; Fornabaio DM
Clin Exp Metastasis; 1988; 6(4):271-84. PubMed ID: 3129225
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812
[TBL] [Abstract][Full Text] [Related]
16. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
17. Autolymphocyte therapy. II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells.
Gold JE; Osband ME
Clin Immunol Immunopathol; 1994 Jun; 71(3):325-32. PubMed ID: 7911078
[TBL] [Abstract][Full Text] [Related]
18. Combination of ionising radiation with hyperthermia increases the immunogenic potential of B16-F10 melanoma cells in vitro and in vivo.
Werthmöller N; Frey B; Rückert M; Lotter M; Fietkau R; Gaipl US
Int J Hyperthermia; 2016; 32(1):23-30. PubMed ID: 26754406
[TBL] [Abstract][Full Text] [Related]
19. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.
DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H
J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
